Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 07:30 ET | Source: InflaRx N.V.

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b...